Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XX Other antineoplastic agents
L01XX72 Tazemetostat
D11485 Tazemetostat hydrobromide (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
EZH2 Inhibitors
Tazemetostat
D11485 Tazemetostat hydrobromide (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D11485 Tazemetostat hydrobromide (JAN/USAN)
Drug groups [BR:br08330]
Transporter substrate
DG01665 ABCB1 substrate
DG03020 Tazemetostat
D11485 Tazemetostat hydrobromide
Transporter inhibitor
DG02864 SLC47A1 inhibitor
DG03020 Tazemetostat
D11485 Tazemetostat hydrobromide
DG03110 SLC47A2 inhibitor
DG03020 Tazemetostat
D11485 Tazemetostat hydrobromide
Target-based classification of drugs [BR:br08310]
Enzymes
Transferases (EC2)
Methyltransferases
EZH2* [HSA_VAR:2146v1]
D11485 Tazemetostat hydrobromide (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11485
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11485
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11485
Drug metabolizing enzymes and transporters [br08309.html]
Drug transporters
D11485
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D11485
Drug groups [BR:br08330]
Transporter substrate
DG01665 ABCB1 substrate
DG03020 Tazemetostat
Transporter inhibitor
DG02864 SLC47A1 inhibitor
DG03020 Tazemetostat
DG03110 SLC47A2 inhibitor
DG03020 Tazemetostat